TIDMSLN

RNS Number : 8944O

Silence Therapeutics PLC

04 October 2019

Director/PDMR Shareholding and Additional Listing

October 4, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on October 4, 4,000 Shares were purchased by David Lemus, Non-Executive Director of the Company, at GBP1.86 per share.

Mr Lemus has also exercised 1,626 Conditional Share Awards at a price of 5p per share. Following the exercise and purchase of shares, David Lemus is interested in 5,626 ordinary shares, being <0.01% of the enlarged issued share capital of the Company.

The Company also announces it has today issued and allotted 1,626 new ordinary shares of 5p each ("New Ordinary Shares") following this exercise of share options under the 2018 Non-Employee Long Term Incentive Plan. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on October 10, 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 78,327,279. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         David Lemus 
     ---------------------------  ---------------------------------------------- 
 2.   Reason for the notification 
     --------------------------------------------------------------------------- 
 a)   Position / status            Non-Executive Director 
     ---------------------------  ---------------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ---------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ---------------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------------------- 
 a)   Description of               Ordinary Shares of 5 pence each in Silence 
       the financial instrument,    Therapeutics plc 
       type of instrument 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc Ordinary 
                                    Shares: 
                                    GB00B9GTXM62 
     ---------------------------  ---------------------------------------------- 
 b)   Nature of the transaction    Exercise of Conditional Share Options 
                                    over Ordinary Shares in Silence Therapeutics 
                                    plc 
 
                                    Purchase of Ordinary Shares in Silence 
                                    Therapeutics plc 
     ---------------------------  ---------------------------------------------- 
 c)   Prices(a) and volume(s)      Exercise Price      Volume 
                                     GBP0.05    1,626 
                                               ------- 
 
 
 
                                    Purchase Price      Volume 
                                     GBP1.86    4,000 
                                               ------- 
     ---------------------------  ---------------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           5,626 Ordinary Shares 
       - Price                       GBP7,521.30 
     ---------------------------  ---------------------------------------------- 
 e)   Date of the transaction      04 October 2019 
     ---------------------------  ---------------------------------------------- 
 f)   Place of the transaction     Exercise - Outside a trading venue 
 
                                    Purchase - London Stock Exchange, AIM 
     ---------------------------  ---------------------------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                          Tel: +44 (0)20 3457 
  Dr David Horn Solomon, Chief Executive Officer    6900 
 Peel Hunt LLP (Nominated Adviser and Broker)      Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                        8900 
 European IR                                       Tel: +44 (0) 20 
  Consilium Strategic Communications                3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                              Tel: +1 (443) 213-0505 
  Westwicke Partners 
  Peter Vozzo 
  peter.vozzo@westwicke.com 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAKELEFPNFFF

(END) Dow Jones Newswires

October 04, 2019 12:21 ET (16:21 GMT)

Grafico Azioni Silence Therapeutics (LSE:SLN)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Silence Therapeutics
Grafico Azioni Silence Therapeutics (LSE:SLN)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Silence Therapeutics